1. Effect of heart rate control with ivabradine on hemodynamic in patients with sepsis: study protocol for a prospective, multicenter, randomized controlled trial.
- Author
-
Zheng J, Wen D, Pan Z, Chen X, Kong T, Wen Q, Zhou H, Chen W, and Zhang Z
- Subjects
- Humans, Prospective Studies, Treatment Outcome, Multicenter Studies as Topic, Middle Aged, Male, Adult, Female, Aged, Cardiovascular Agents therapeutic use, Cardiovascular Agents adverse effects, Time Factors, Ivabradine therapeutic use, Heart Rate drug effects, Sepsis drug therapy, Sepsis physiopathology, Hemodynamics drug effects, Randomized Controlled Trials as Topic
- Abstract
Introduction: Sepsis, a life-threatening syndrome, is often accompanied by tachycardia in spite of hypovolemia and hypotension have been corrected. Recently, relevant studies have shown that sustained tachycardia in sepsis was related to high mortality, and appropriate control of heart rate (HR) could improve prognosis. Ivabradine reduces HR directly without a negative inotropic effect through inhibition of the I
f ionic current, which is different from the traditional rate control drug (beta-blockers)., Methods and Analysis: This is a prospective, multicenter, randomized, open label study designed to investigate the effect of heart rate control with ivabradine on hemodynamic in patients with sepsis. Our study will enroll 172 patients with sepsis as defined by The Third International Consensus Definitions for Sepsis and Septic Shock criteria with sinus rate of 95 bpm or higher despite a hemodynamic optimization. Patients will be randomly assigned to standard treatment group (GS) or ivabradine group (GI, standard treatment for sepsis plus enteral ivabradine). Patients in GI will receive ivabradine to maintain HR between 70 and 94 bpm. The primary outcome is the difference of a reduction in HR below 95 bpm and the effect of ivabradine on hemodynamics between GI and GS group within the first 96 h after randomization. The secondary outcomes include organ function measures, the difference in SOFA score, incidence of adverse events, need for organ support, length of ICU stay, and 28-day overall mortality., Discussion: There are limited studies on ivabradine to control heart rate in patients with sepsis. Our study aims to evaluate whether direct sinus node inhibition can improve hemodynamics, as well as its impact on organ function and prognosis in patients with sepsis, so as to provide evidence for the safe usage in clinical practice., Trial Registration: ClinicalTrials.gov NCT05882708. Registered on May 11, 2023, https://clinicaltrials.gov/ct2/show/NCT05882708 ., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF